Arrakis Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
88
- Latest Deal Type
-
Later Stage VC
- Investors
-
15
Arrakis Therapeutics General Information
Description
Developer of a drug discovery platform designed to find new points of therapeutic intervention. The company's platform integrates RNA bioinformatics, chemical biology tools, chemical and biological assays, and RNA-directed medicinal chemistry, enabling physicians to treat a range of diseases including neurology, oncology, and rare genetic diseases.
Contact Information
Website
www.arrakistx.comCorporate Office
- 828 Winter Street
- Waltham, MA 02451
- United States
Corporate Office
- 828 Winter Street
- Waltham, MA 02451
- United States
Arrakis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 01-Jan-2020 | Completed | Product Development | |||
| 3. Early Stage VC (Series B) | 10-Apr-2019 | Completed | Product Development | |||
| 2. Early Stage VC (Series A) | 02-Mar-2017 | $38.5M | $40.5M | Completed | Product Development | |
| 1. Seed Round | 01-Jan-2015 | $2M | $2M | Completed | Startup |
Arrakis Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Arrakis Therapeutics Comparisons
Industry
Financing
Details
Arrakis Therapeutics Competitors (128)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Amunix Pharmaceuticals | Formerly PE-Backed | South San Francisco, CA | ||||
| Editas Medicine | Formerly VC-backed | Cambridge, MA | ||||
| StemiRNA Therapeutics Biotech | Venture Capital-Backed | Shanghai, China |
Arrakis Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Arrakis Therapeutics Patents
Arrakis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4423268-A1 | Rna degraders and uses thereof | Pending | 28-Oct-2021 | ||
| AU-2018374389-A1 | Nucleic acid-binding photoprobes and uses thereof | Pending | 30-Nov-2017 | ||
| EP-3717009-A1 | Nucleic acid-binding photoprobes and uses thereof | Pending | 30-Nov-2017 | ||
| CA-3078540-A1 | Nucleic acid-binding photoprobes and uses thereof | Pending | 30-Nov-2017 | ||
| EP-3717009-A4 | Nucleic acid-binding photoprobes and uses thereof | Pending | 30-Nov-2017 | C07D401/14 |
Arrakis Therapeutics Executive Team (14)
| Name | Title | Board Seat |
|---|---|---|
| Michael Gilman Ph.D | Chief Executive Officer & Chairman | |
| Jacques Dumas Ph.D | Chief Scientific Officer | |
| William Tang | Director of Finance | |
| Jennifer Petter Ph.D | Co-Founder & Chief Innovation Officer | |
| James Mutamba Ph.D | Chief Business Officer |
Arrakis Therapeutics Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alan Walts Ph.D | Arrakis Therapeutics | Board Observer | |
| Christopher O'Donnell Ph.D | Pfizer Ventures | Board Member | |
| Colleen Cuffaro Ph.D | Canaan Partners | Board Member | |
| Elaine Jones Ph.D | Pfizer Ventures | Board Observer & Board Member | |
| Jakob Loven Ph.D | Nextech Invest | Board Member |
Arrakis Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Arrakis Therapeutics Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Venture Investments | Venture Capital | Minority | ||
| GV | Corporate Venture Capital | Minority | ||
| HBM Healthcare Investments | Venture Capital | Minority | ||
| HBM Partners | Venture Capital | Minority | ||
| Nextech Invest | Venture Capital | Minority |
Arrakis Therapeutics FAQs
-
When was Arrakis Therapeutics founded?
Arrakis Therapeutics was founded in 2015.
-
Who is the founder of Arrakis Therapeutics?
Russell Petter Ph.D, Jennifer Petter Ph.D, Rajesh Parekh Ph.D, and Henri Termeer are the founders of Arrakis Therapeutics.
-
Who is the CEO of Arrakis Therapeutics?
Michael Gilman Ph.D is the CEO of Arrakis Therapeutics.
-
Where is Arrakis Therapeutics headquartered?
Arrakis Therapeutics is headquartered in Waltham, MA.
-
What is the size of Arrakis Therapeutics?
Arrakis Therapeutics has 88 total employees.
-
What industry is Arrakis Therapeutics in?
Arrakis Therapeutics’s primary industry is Drug Discovery.
-
Is Arrakis Therapeutics a private or public company?
Arrakis Therapeutics is a Private company.
-
What is Arrakis Therapeutics’s current revenue?
The current revenue for Arrakis Therapeutics is .
-
How much funding has Arrakis Therapeutics raised over time?
Arrakis Therapeutics has raised $115M.
-
Who are Arrakis Therapeutics’s investors?
Alexandria Venture Investments, GV, HBM Healthcare Investments, HBM Partners, and Nextech Invest are 5 of 15 investors who have invested in Arrakis Therapeutics.
-
Who are Arrakis Therapeutics’s competitors?
Renova Therapeutics, Dicerna Pharmaceuticals, Amunix Pharmaceuticals, Editas Medicine, and StemiRNA Therapeutics Biotech are some of the 128 competitors of Arrakis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
